This study evaluated the epidemiological evidence for serum insulin-like growth factor-1 (IGF-I) levels and the risk of prostate cancer, and the results indicate that high serum IGF-I levels are associated with an increased risk of prostate cancer. This evidence concerns the gene IGF1 and prostate carcinoma.